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Mutations in several genes encoding transcription factors of the
hepatocyte nuclear factor (HNF) cascade are associated with
maturity-onset diabetes of the young (MODY), a monogenic
form of early-onset diabetes mellitus. The ability of the orphan
nuclear receptor small heterodimer partner (SHP, NR0B2) to
modulate the transcriptional activity of MODY1 protein, the
nuclear receptor HNF-4a, suggested SHP as a candidate MODY
gene. We screened 173 unrelated Japanese subjects with early-
onset diabetes for mutations in this gene and found five differ-
ent mutations (H53fsdel10, L98fsdel9insAC, R34X, A195S, and
R213C) in 6 subjects as well as one apparent polymorphism
(R216H), all present in the heterozygous state. Interestingly, all
of the subjects with the mutations were mildly or moderately
obese at onset of diabetes, and analysis of the lineages of these
individuals indicated that the SHP mutations were associated
with obesity rather than with diabetes. Therefore, an additional
group of 101 unrelated nondiabetic subjects with early-onset
obesity was screened for mutations in the SHP gene. Two of the
previously observed mutations (R34X and A195S) and two
additional mutations (R57W and G189E) were identified in 6
subjects, whereas no mutations were identified in 116 young
nondiabetic lean controls (P 5 0.0094). Functional studies of
the mutant proteins show that the mutations result in the loss of
SHP activity. These results suggest that genetic variation in the
SHP gene contributes to increased body weight and reveal a
pathway leading to this common metabolic disorder in
Japanese.
nuclear receptor u maturity-onset diabetes of the young u
insulin secretion u body weight u hepatocyte nuclear factor
Heterozygous mutations in genes encoding transcriptionfactors in the hepatocyte nuclear factor (HNF) regulatory
cascade (1) are associated with an early-onset autosomal
dominant form of diabetes mellitus, maturity-onset diabetes of
the young (MODY) (2). To date, diabetes-associated muta-
tions have been found in three members of this regulatory
network, HNF-1a, -1b, and -4a (MODY3, 5, and 1, respec-
tively) (3–6). These forms of MODY are characterized pri-
marily by defective insulin secretion with normal body weight
(7–9). In contrast, forms of early-onset autosomal-dominant
type 2 diabetes that are not linked to known MODY genes are
often characterized by insulin resistance with high body
weight, rather than by pure pancreatic b-cell defects (10). It is
not known whether obesity-associated MODY genes or other
common modifying factors are responsible for these pheno-
typic features.
The protein small heterodimer partner (SHP; also called
NROB2 for nuclear receptor subfamily 0, group B, member 2),
an atypical orphan nuclear receptor that lacks a conventional
DNA-binding domain, interacts with a number of other nu-
clear receptors, including HNF-4a, and inhibits their tran-
scriptional activity (11–17). SHP is expressed in the liver and
has recently been suggested to regulate cholesterol homeosta-
sis by an inhibitory effect on the expression of CYP7A, the
rate-limiting enzyme in bile acid formation (18, 19). SHP is
also found in other tissues, including pancreatic b cells (un-
published data), suggesting a role for this orphan receptor in
the regulation of HNF-4a activity. Accordingly, the SHP gene
is a plausible candidate MODY gene. We screened the SHP
gene for mutations in Japanese subjects with early-onset
nonketotic diabetes and identified six different mutations.
Interestingly, five of the six mutations were associated with
obesity rather than the diabetic phenotype in these families.
An additional screen of 101 unrelated subjects with early-onset
obesity revealed four mutations, two of which were not
previously known and two of which appeared in the diabetic
subjects. Functional analysis demonstrated that the mutant
SHP proteins showed decreased ability to inhibit HNF-4a
transactivation. The association of loss of SHP activity with
increased body weight suggests an unexpected role for this
orphan receptor in obesity.
Subjects and Methods
Mutation Analysis. We studied 173 subjects with type 2 diabetes
diagnosed before 15 years of age, because our previous study of
MODY3 in young Japanese patients suggested that many of
these patients have a monogenic form of diabetes (20). Of these
subjects, 86 were obese and 87 were nonobese at diagnosis [obese
vs. nonobese: body mass index (BMI) 28.4 6 3.4 kgym2 vs. 20.1 6
2.0 kgym2]. BMI .25 kgym2 is the cut-off for obesity in this
study, according to the criteria of the Japan Society for the Study
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of Obesity; there is no difference in BMI criteria by sex in
Japanese (21). Appropriate informed consent was obtained from
all of the subjects examined, including volunteer control subjects.
The two exons and flanking regions of the human SHP gene
(GenBank accession no. AF044316) were screened for muta-
tions by direct sequencing of the amplified polymerase chain
reaction (PCR) products, using specific primer pairs and an ABI
Prism dRhodamine Terminator Cycle Sequencing FS Ready
Reaction Kit (Applied Biosystems). The sequencing reactions
were analyzed by an Applied Biosystems DNA sequencer model
377. The presence or absence of each mutation in 190 unrelated
nondiabetic and nonobese control subjects (hemoglobin A1c
,5.6% and BMI ,23 kgym2) was first assessed by direct
sequencing of the PCR products of the appropriate exon. For the
association study, the two exons and flanking regions of the gene
were also screened for mutations by direct sequencing in 101
young unrelated nondiabetic obese subjects (age 13.5 6 5.1
years; BMI 31.0 6 6.8 kgym2) and 116 control subjects (age
11.9 6 3.2 years; BMI 20.0 6 2.7 kgym2).
Wild-Type and Mutant Plasmid Constructs. SHP genes carrying the
mutations identified were generated by PCR-based site-directed
mutagenesis and cloned in the expression vector pCMV-6b. The
wild-type SHP and HNF-4a were also cloned in pCMV-6b and
pcDNA3.1 to generate pCMV-SHP and pcDNA-HNF-4a, re-
spectively. For luciferase reporter assay, the promoter region
(nucleotide 2129y1195) (22) of the human HNF-1a gene was
inserted into the pGL3-Basic Reporter vector (Promega) to
generate pGL3-HNF1.
Transient Transfection Assay. Liver-derived HepG2 and insulin-
producing MIN6-m9 cells (1 3 105) were grown in 24-well plates
containing Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% or 15% fetal calf serum, respectively, and
with 72 mM 2-mercaptoethanol for MIN6-m9 cells. The cells
were transfected with 3 ml of liposomal Fugene 6 solution
(Roche Molecular Biochemicals), 333 ng of pGL3-HNF-1a, 25
ng of pcDNA-HNF-4a, 0–625 ng of test DNA, and 17 ng of pRL
(Renilla luciferase)-SV40. Luciferase reporter activity was mea-
sured by using a Dual-Luciferase Reporter Assay System (Pro-
mega) according to the manufacturer’s instructions. Renilla
luciferase activity was used to normalize transfection efficiencies
among experiments.
Fig. 1. Families with mutations in NROB2. Circles represent females; squares, males; rotated squares, sex unspecified. Individuals with both type 2 diabetes
and obesity are indicated by black symbols, those with diabetes and no obesity are indicated by shaded symbols, and those with obesity andyor overweight
at birth without diabetes are indicated by diagonal symbols. Arrow indicates the proband of each family. The NROB2 genotype is indicated below the
symbol: N, normal; M, mutant; nd, not determined. Mutations (family): H53fsdel10 (Y19), L98fsdel9insAC (eT23), R34X (Y118 and Y120), R213C (K63), and
A195S (NT5503). Age (years) at diagnosis of diabetes is indicated below the genotype. The oblique lines present between subjects II-2 and II-3 in Y118 and
between subjects I-1 and I-2 in Y120 mean divorce.
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Statistical Analyses. Pairwise logarithm of odds (LOD) scores
were estimated by using the LINKAGE package and assuming an
equal recombination frequency between males and females.
The mode of inheritance was assumed to be dominant. The
mutation frequency was assumed to be 0.005. When the
quantity data were classified into two levels, exact P values for
the simple linear rank statistics based on Wilcoxon scores were
obtained. When the quality data were classified into two levels,
Fisher’s exact test was used. BMI and weight at birth were
adjusted by two-way analysis of variance (ANOVA). Individual
ages were classified into three groups; 19 years and below,
20–49 years, and 50 years and over. All computations were
performed with the Statistical Analysis System (SAS) version
6.12 (23). Data obtained by luciferase reporter assay were
analyzed by the Student t test, using STATVIEW 4.51 (Abacus
Concepts, Berkeley, CA).
Results
Identification of SHP Mutations. The human SHP gene (gene
symbol, NROB2) has been localized to chromosome 1p36.1
(14). It consists of two exons and spans approximately 2 kb. To
test the possibility that it could be a MODY gene, 173
unrelated Japanese subjects with early-onset nonketotic dia-
betes were examined for SHP gene mutations. The two exons
and f lanking sequences were screened for mutations by direct
sequencing of PCR products. This analysis revealed six differ-
ent mutations, all in a heterozygous state, in seven subjects.
The mutations include two frameshift mutations, H53fsdel10
(deletion of 10 bases starting at codon 53 for His) and
L98fsdel9insAC (deletion of 9 bases and insertion of a dinu-
cleotide AC at codon 98 for Leu), one nonsense mutation
R34X (amino acid replacement of Arg codon 34 by terminator)
that was found in two subjects, and three missense mutations,
R213C, R216H, and A195S (replacements of Arg codons 213
and 216 by Cys and His codons, respectively, and Ala codon
195 by Ser). The H53fsdel10, L98fsdel9insAC, and R34X
mutations are truncations that would completely inactivate the
putative ligand-binding function and also delete C-terminal
sequences associated with transcriptional repression (15, 16).
The residues affected by the missense mutations, Arg-213,
Ala-195, and Arg-216, are conserved in mammalian SHP
sequences. The H53fsdel10, L98fsdel9insAC, R34X, R213C,
and A195S mutations were not found on screening 190 control
subjects (380 alleles). However, the R216H allele was present
in 2 of 190 control subjects, suggesting that it may be a
polymorphism that is not pathogenic. This suggestion was
confirmed by the lack of effect of this alteration on SHP
function (see below).
Genotyping of other family members showed that the muta-
tions found in NROB2 did not cosegregate with early-onset
diabetes (Fig. 1). In fact, the combined LOD score for early-
onset diabetes was 2‘ at u 5 0. Strikingly, however, all subjects
with the mutations were mildly or moderately obese, with a
combined LOD score for obesity of 2.31 at u 5 0.
On the basis of the potential linkage of the SHP gene with
obesity, an additional association study of young unrelated
nondiabetic individuals with (101 subjects) or without (116
subjects) obesity was carried out. Screening the gene for muta-
tions by direct sequencing in these subjects resulted in the
identification of four different mutant alleles in 6 subjects (5.9%)
Table 1. Clinical profiles of probands with NROB2 mutations
Family ID
mutation
Y19
H53fsdel10
eT23
L98fsdel9insAC
K63
R213C
Y118
R34X
Y120
R34X
NT5503
A195S
Reference
ranges
Age at diagnosis, yr 7 15 12 13 12 14 —
Current age, yr 14 46 35 17 18 19 —
BMI at diagnosis, kgym2 25.1 39.5 25.0 33.8 25.7 33.2 ,23
Weight at birth,* g 5,005 ? 4,000 3,200 4,500 ? Ref. 24
OGTT†
0 min 13.2 (66) 13.6 (78) 7.0 (68) 7.2 (309) 7.5 (150) 6.3 (220) 3.3–6.2 (,60)
30 min 23.2 (108) 18.6 (162) 12.2 (264) 11.9 (540) 14.4 (294) 10.6 (966) (138–462)
120 min 23.2 (84) 21.8 (380) 10.5 (386) 14.3 (1,080) 18.6 (372) 12.6 (1,170) 6.7. (66–198)
AST, IUzliter21 11 12 26 96 16 208 10–40
ALT, IUzliter21 14 7 ND 148 17 357 5–40
LDH, IUzliter21 404 303 353 464 380 667 230–420
g-GTP, IUzliter21 9 6 ND 163 4 70 6–14
T-Chol, mgzdl21 164 190 233 149 152 38 120–219
TG, mgzdl21 66 132 ND 170 182 76 35–195
NEFA, mEqzliter21 ND 0.17 ND 0.86 0.79 0.87 0.15–0.55
HDL, mgzdl21 68 94 43 54 36 32 35–80
LH, mIUzml21 2.5 4.4 5.1 0.81 1.6 ND 0.6–16.8
FSH, mIUzml21 10.3 4.2 7.0 1.96 4.54 ND 1.6–19
Estradiol, pgzml21 ,10 21.1 ND 31.2 10.1 ND 8–60
Testosterone, ngzml21 ND 23.2 ND 2.48 2.27 ND ,86
Cortisol, mgzdl21 ND 5.4 5.5 13.2 12.6 7.2 5–15
ACTH, pgzml21 ND 30 ND ND 28 ND ,60
Free T4, ngzdl21 1.32 0.8 1.0 1.01 1.01 ND 0.8–1.7
Leptin, ngzml21 8.8 22.4 5.5 16 6.5 ND
IU, international unit; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; g-GTP, g-glutamyl transpeptidase;
T-Chol, total cholesterol; TG, triglyceride; HDL, high density lipoprotein cholesterol; NEFA, nonesterified fatty acid; LH, luteinizing hormone; FSH, follicle-
stimulating hormone; ACTH, adrenocorticotropic hormone; T4, thyroxine; ND, not done. Biochemical data in subjects Y19, Y118, Y120, and NT5503 were
obtained at diagnosis of diabetes. Plasma leptin levels were recently measured (5–30 years after the diagnosis).
*Subject Y118 was born immaturely due to mother’s preeclampsia (birth weight . mean 1 1.0 SD). The birth weight of subject NT5503 is unknown. The birth
weight of the other subjects was higher than the mean 1 1.5 SD. Reference ranges for weight at birth in Japanese are described by Nishida et al. (24).
†OGTT, oral glucose tolerance test; the first numbers are plasma glucose in mmolzliter21, and the numbers in parentheses are immunoreactive insulin in
pmolzliter21. Reference values for immunoreactive insulin are in the range of mean 6 SD.
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in the obese group and none (0%) in the nonobese group (P 5
0.0094). Two of the mutant alleles had already been identified in
the diabetic subjects (R34X and A195S), whereas two (R57W
and G189E) were novel. Because the LOD score for diabetes was
indicative of no linkage (2‘ at u 5 0), the diabetic and
nondiabetic subjects were pooled. The overall frequency of the
NROB2 mutations in early-onset obesity in this study was 6.3%
(12y187) and 0% (0y203) in nonobese subjects (P 5 0.00012).
These results demonstrate a clear association of SHP gene
mutations with obesity.
The available clinical features of the six diabetic subjects
with the mutations are summarized in Table 1. All of them
were obese at the time of diagnosis of diabetes. Interestingly,
the birth weights of these subjects also were also at least 1
standard deviation higher than the mean birth weight in
Japanese at each corresponding gestational age (24), including
that of subject Y118, who was born prematurely at ’35 weeks
because of the mother’s preeclampsia. The clinical records of
subjects eT23 and NT5503 at birth were not available. Com-
parisons of genotype with BMI and birth weight of family
members indicate that the SHP mutations are associated
significantly with both high birth weight (P 5 0.0082) and
obesity (P 5 0.0036) in these lineages (Table 2). Because many
genetic and environmental factors are shared among family
members, the significant association of the SHP genotype with
these phenotypes strongly suggests that the mutations contrib-
ute to the increase of body weight in the affected subjects.
Clinical records indicate that none of the carrier mothers had
gestational diabetes. The subject with the polymorphism
R216H had normal birth weight (3,110 g, 39 weeks, multipara,
mean 5 3,080 g).
Plasma insulin levels in these diabetic subjects at onset were
at least 1 standard deviation higher than the mean value in
controls. The affected individuals also appear to have de-
creased insulin sensitivity as estimated from the fasting insulin
and glucose levels by using homeostasis model assessment
(HOMA) (25, 26). As shown in Table 1, the plasma levels of
growth-related steroid hormones in the subjects examined
were within normal limits. The levels of leptin also were
appropriate to the degree of obesity. There were no consistent
alterations in serum lipids. Liver dysfunction and fatty liver
were observed at diagnosis in subjects Y118 and NT5503.
However, subject Y120, who has the same mutation (R34X) as
Y118, had normal liver function. Although one might expect
that the nonsense or frameshift mutations would cause more
severe symptoms in the affected subjects than do missense
mutations, there is no obvious correlation between the type of
mutation and the degree of obesity. All subjects with the
NROB2 mutations had normal intellectual development and
fertility. The clinical features of the six nondiabetic volunteer
children with elevated BMI who were found to have mutations
are not available because consent for further examinations was
not obtained.
Functional Analysis of Mutant Proteins. To determine whether the
mutations identified in MODY families alter the function of
the SHP protein, the effect of the wild-type and mutant
proteins on HNF-4a-mediated transactivation of HNF-1a
gene transcription was examined. HNF-4a efficiently in-
creased reporter gene activity directed by transcription from
the HNF-1a gene promoter in liver HepG2 and insulin-
producing MIN6-m9 cells (Fig. 2A). Expression of wild-type
SHP significantly decreased both endogenous and exogenous
HNF-4a transactivation activities in HepG2 cells, confirming
that SHP is a negative regulator of HNF-4a (ref. 15 and Fig.
2B). Because the expression of endogenous HNF-4a is low in
MIN6-m9 cells, the effects of the SHP mutant proteins on
exogenous HNF-4a activity can be readily monitored in this
cell line. When the H53fsdel10, L98fsdel9insAC, R34X,
A195S, and R213C mutant proteins were expressed with
HNF-4a in MIN6-m9 cells, a significant reduction in suppres-
sive activity of the mutant proteins was observed. The R216H
protein showed no significant reduction in activity, consistent
with this alteration being a polymorphism (Fig. 2C). The two
Fig. 2. Inhibition of transactivation activity of HNF-4a by wild-type and
mutant SHP. (A) HNF-4a generated significant increases in luciferase reporter
activity directed by the HNF-1a gene promoter in HepG2 and MIN6-m9 cells.
(B) Wild-type SHP significantly decreased transactivation activity of both
exogenous (25 ng, F) and endogenous (E) HNF-4a in HepG2 cells. (C) The
relative luciferase activity (fireflyyRenilla) of each construct at 0, 25, and 125
ng of SHP was measured in MIN6-m9 cells (n 5 5 in each experiment). Percent
activity in relation to basic HNF-4a activity is shown as mean 6 SD. *, P , 0.05;
**, P , 0.01.
Table 2. Genotype association with BMI and birth weight in
MODY families
Genotype n BMI, kgym2 P n
Weight at
birth, g P
NN 9 22.76 6 2.42
0.0036
8 2,707.1 6 299.7
0.0082
NM 15 28.83 6 1.18 8 3,899.6 6 228.9
In Japan, each pregnant woman is expected to report her pregnancy to
the municipal government and receive a Maternal and Child Health Hand-
book, a health record from pregnancy through child delivery. Data are
from these records. Results are mean 6 SD. Statistical analyses were
performed as described in Subjects and Methods. N, normal SHP; M, mutant
SHP.
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additional mutations identified in nondiabetic subjects with
obesity also showed significantly reduced ability to inhibit
HNF-4a transactivation.
Discussion
The identification of genes responsible for monogenic forms of
obesity has led to a better understanding of the molecular and
physiological basis of this common metabolic condition. In
humans, five such genes have been described to date. Muta-
tions in the genes for leptin, the leptin receptor, prohormone
convertase 1 (PC1), and pro-opiomelanocortin (POMC) lead
to a distinct phenotype of morbid obesity and various hypo-
thalamic and pituitary disorders with a recessive inheritance
(27–31). Mutations in the melanocortin-4 receptor (MC4-R)
gene cause a nonsyndromic phenotype of morbid obesity with
dominant inheritance (refs. 32 and 33 and Table 3). The
proteins encoded by these genes are functionally related in the
central signaling system of energy homeostasis and feeding
behavior (34). Leptin, a cytokine secreted from adipose tis-
sues, interacts with its receptor in the hypothalamus to mod-
ulate the expression of central signaling proteins including
POMC, which in turn regulates both energy expenditure and
feeding. a-Melanocyte-stimulating hormone (MSH), pro-
cessed from the precursor POMC by the proteolytic enzymes
PC1 and carboxypeptidase E, also inf luences energy expen-
diture and food intake by activation of MC4-R in the hypo-
thalamus. In contrast, the subjects with SHP gene mutations
exhibited no endocrine abnormalities in pituitary or hypothal-
amus and showed a distinct, relatively mild obesity. Thus, these
NROB2 mutations reveal a pathway to increased weight that is
apparently independent of the hypothalamic pathway. This
pathway could be related to effects of SHP on one or more of
a number of nuclear receptors associated with metabolic
regulation. These include the steroid, retinoid, and thyroid
hormone receptors, the orphan HNF-4a, and particularly the
peroxisome proliferator-activated receptors (PPARs), which
play a key role in adipogenesis (35).
Mutations in NROB2 are associated with a dominantly
inherited form of early-onset obesity similar to that in patients
with the most common form of obesity (25–30 kgym2) in
Japanese (21, 36). Most studies examining the complications
associated with obesity have been based on data from Western
populations, and it has been well recognized that the standard
World Health Organization (WHO) criteria classifying obesity
and preobesity by using BMI (obesity .30 kgym2; preobesity
.25 kgym2) is not appropriate in the Asia–Pacific region.n For
example, only ’2% of Japanese, Korean, and Chinese popu-
lations are classified as obese when the WHO criteria are used,
and increased morbidity risks occur in people with much lower
BMIs in the Asia–Pacific region (footnote n; refs. 36–40). It is
tempting to speculate, therefore, that NROB2 mutations are a
component of the genetic background of obesity in Japanese,
although neither the significance of such mutations in the
development of adult-onset obesity in this population nor the
prevalence of mutations in Western populations is known at
present.
Interestingly, NROB2 mutations are also associated with high
birth weight. Because SHP inhibits HNF-4a, the loss of SHP
function should lead to increased activity of HNF-4a, resulting
in increased insulin secretion. Because insulin is one of the key
hormones in adipogenesis, increased insulin secretion occurring
in the fetus might well increase intrauterine growth (41–43).
Such increased fetal growth could also underlie the postnatal
obesity in the affected subjects.
Finally, it is clear that the activity of SHP could be regulated
by yet-unidentified ligands, and the results described here sug-
gest that such SHP agonists or antagonists could have a signif-
icant effect on body weight. Accordingly, identification and
characterization of possible SHP ligands and the partner pro-
teins that mediate its effects should provide new insight into the
mechanisms of fetal growth and energy expenditure.
We are grateful to all of the patients with early-onset diabetes andyor
obesity cooperating in this study and to their referring physicians,
and we are grateful for the encouragement of Dr. T. Takeuchi
(Gunma University) and the Meeting of Active Pediatric Endocrinol-
nWorld Health Organization (Western Pacific Region) and IASO (The International Associ-
ation for the Study of Obesity)yIOTF (The International Obesity Task Force) (2000) Web
site: http:yywww.idi.org.auyobesityreport.hm.
Table 3. Comparison of phenotypic features of monogenic forms of obesity
Gene Obesity Birth weight Endocrine abnormalities Hyperphagia Inheritance Chromosome
LEP Severe Normal Low leptin
Hypogonadism
High thyroid stimulating hormone
High insulin
1 Recessive 7q31.3
LEPR Severe ? High leptin
Pituitary dysfunction
Hypogonadotrophic hypogonadism
Hypothalamic hypothyroidism
Sympathetic dysfunction
High insulin
1 Recessive 1p31
POMC Severe Normal Red hair pigmentation
ACTH deficiency, hypocortisolism
Low a-MSH
1 Recessive 2p23.3
PC1 Severe ? Hypogonadotrophic hypogonadism
Hypocortisolism
High proinsulin, low insulin
Postprandial hypoglycemia
High POMC
? Recessive 5q1.5–2.1
MC4-R Severe Normal Not observed 1 Dominant 18q22
NROB2 Mild High Mild hyperinsulinemia 2 Dominant 1p36.1
LEP, leptin; LEPR, leptin receptor; POMC, pro-opiomelanocortin; PC1, prohormone convertase 1; MC4-R, melanocortin-4 receptor;
ACTH, adrenocorticotropic hormone; a-MSH, a-melanocyte-stimulating hormone.
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